7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Xing L et al. Osteoclast precursors, RANKL/RANK, and immunology. 2005 Immunol. Rev. pmid:16313338
Tanaka S et al. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. 2005 Immunol. Rev. pmid:16313339
Horowitz MC et al. B cells and osteoblast and osteoclast development. 2005 Immunol. Rev. pmid:16313346
Clowes JA et al. The role of the immune system in the pathophysiology of osteoporosis. 2005 Immunol. Rev. pmid:16313351
Walsh NC et al. Rheumatic diseases: the effects of inflammation on bone. 2005 Immunol. Rev. pmid:16313352
Liu Y et al. [Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts]. 2005 Zhong Yao Cai pmid:16568663
Wang YD et al. [Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. 2005 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:16355616
Xiao HL et al. [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. 2005 Yi Chuan pmid:16257908
Liu W et al. Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. 2005 J. Biol. Chem. pmid:16260781
Hormdee D et al. Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. 2005 Clin. Exp. Immunol. pmid:16297161
Geusens P and Reid D Newer drug treatments: their effects on fracture prevention. 2005 Best Pract Res Clin Rheumatol pmid:16301192
Hamdy NA Osteoprotegerin as a potential therapy for osteoporosis. 2005 Curr Osteoporos Rep pmid:16303111
Wiercinska-Drapalo A et al. Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. 2005 Prostaglandins Other Lipid Mediat. pmid:16303613
Burton DW et al. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. 2005 Prostate pmid:15389781
Zahanich I et al. Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. 2005 J. Bone Miner. Res. pmid:16059635
Cao JJ et al. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. 2005 J. Bone Miner. Res. pmid:16059637
Terpos E et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. 2005 Leukemia pmid:16079895
Stenman UH et al. Prognostic value of serum markers for prostate cancer. 2005 Scand J Urol Nephrol Suppl pmid:16019759
Guang-da X et al. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. 2005 J. Clin. Endocrinol. Metab. pmid:16046585
Kazama JJ et al. Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. 2005 Clin. Nephrol. pmid:16047647
Olesen P et al. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. 2005 Diabetologia pmid:15700136
Pantouli E et al. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. 2005 Biochem. Biophys. Res. Commun. pmid:15721297
Korcok J et al. P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. 2005 J. Biol. Chem. pmid:15722352
Kiviranta R et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. 2005 Bone pmid:15664014
Avbersek-Luznik I et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? 2005 Nephrol. Dial. Transplant. pmid:15665031
Bhatia P et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. 2005 Clin. Cancer Res. pmid:15671541
Schneider HG and Sentry J Multiple myeloma. 2005 N. Engl. J. Med. pmid:15736296
Bock O et al. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. 2005 J. Pathol. pmid:15726648
Skládal P et al. Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. 2005 Biosens Bioelectron pmid:15741072
Mosheimer BA et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. 2005 J. Clin. Endocrinol. Metab. pmid:15728209
Kanno T et al. Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. 2005 J. Oral Maxillofac. Surg. pmid:15742288
Han KO et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. 2005 Clin. Endocrinol. (Oxf) pmid:15730418
Nagasaki T et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. 2005 Eur. J. Endocrinol. pmid:15757850
Rhee EJ et al. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. 2005 Am. J. Obstet. Gynecol. pmid:15846185
Rasmussen LM and Ledet T Osteoprotegerin and diabetic macroangiopathy. 2005 Horm. Metab. Res. pmid:15918117
Tanabe N et al. IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. 2005 Life Sci. pmid:15921993
Zhou YQ et al. [OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. 2005 Shanghai Kou Qiang Yi Xue pmid:16155701
Crisafulli A et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. 2005 Clin. Sci. pmid:15926884
Holen I et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? 2005 Breast Cancer Res. Treat. pmid:16155791
Mahamed DA et al. G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. 2005 Diabetes pmid:15855336
Hong JS et al. Maternal plasma osteoprotegerin concentration in normal pregnancy. 2005 Am. J. Obstet. Gynecol. pmid:16157103
Leder BZ and Finkelstein JS Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. 2005 Osteoporos Int pmid:15856361
Mazziotti G et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. 2005 J. Bone Miner. Res. pmid:15746993
Galli C et al. Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. 2005 J. Periodontol. pmid:15857069
Stolina M et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. 2005 J. Bone Miner. Res. pmid:16160733
Corey E et al. Osteoprotegerin in prostate cancer bone metastasis. 2005 Cancer Res. pmid:15753366
Suzuki K et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. 2005 Diabetes Res. Clin. Pract. pmid:15860239
Yasuda H [OPG, anti-rANKL antibody]. 2005 Nippon Rinsho pmid:16164225
Moschen AR et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. 2005 Gut pmid:15753532
Choi BK et al. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. 2005 J. Periodontol. pmid:15898943
Mandelin J et al. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. 2005 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:15768436
Crisafulli A et al. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. 2005 Menopause pmid:15772566
Mizuno N et al. Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. 2005 Cell Biol. Int. pmid:15774307
Indridason OS et al. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. 2005 Osteoporos Int pmid:15776220
Deftos LJ Treatment of Paget's disease--taming the wild osteoclast. 2005 N. Engl. J. Med. pmid:16135831
Li F et al. Annexin II stimulates RANKL expression through MAPK. 2005 J. Bone Miner. Res. pmid:15940368
Cundy T et al. Recombinant osteoprotegerin for juvenile Paget's disease. 2005 N. Engl. J. Med. pmid:16135836
Sen O et al. The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. 2005 Neurol. Res. pmid:15949247
Bock O et al. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. 2005 Br. J. Haematol. pmid:15982347
Heinrich J et al. CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. 2005 Arch. Oral Biol. pmid:16137499
Fiore CE et al. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. 2005 Osteoporos Int pmid:15983730
Avignon A et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. 2005 Diabetes Care pmid:16123486
Atkins GJ et al. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. 2005 J. Cell. Physiol. pmid:15573398
Amizuka N et al. Histological evaluation for "bone quality" on two mouse models with different bone remodeling. 2005 J. Bone Miner. Metab. pmid:15984413
Ziegler S et al. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. 2005 Metab. Clin. Exp. pmid:15988704
Sakai A et al. Osteoclast development in immobilized bone is suppressed by parathyroidectomy in mice. 2005 J. Bone Miner. Metab. pmid:15616888
Sasaki N et al. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). 2005 J. Bone Miner. Metab. pmid:15616893
Masui T et al. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. 2005 Biomaterials pmid:15576143
Andelković Z et al. [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. 2005 Jul-Aug Med. Pregl. pmid:16296579
Palma MA and Body JJ Usefulness of bone formation markers in breast cancer. 2005 Jul-Sep Int. J. Biol. Markers pmid:16240842
Contractor T et al. Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. 2005 Mar-Apr In Vivo pmid:15796195
Buemi M et al. Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. 2005 Mar-Apr J. Nephrol. pmid:15931642
Gorczynski RM et al. Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. 2005 May-Jun Acta Astronaut pmid:15835039
Pettersen I et al. Osteoprotegerin is expressed in colon carcinoma cells. 2005 Nov-Dec Anticancer Res. pmid:16309167
Kraj M et al. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. 2005 Sep-Oct Arch. Immunol. Ther. Exp. (Warsz.) pmid:16314829
Zojer N et al. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. 2005 Sep-Oct Anticancer Res. pmid:16101188
Miller CS et al. Salivary biomarkers of existing periodontal disease: a cross-sectional study. 2006 J Am Dent Assoc pmid:16570465
Mazziotti G et al. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. 2006 Eur. J. Endocrinol. pmid:16498049
Iwasaki Y et al. Uremic toxin and bone metabolism. 2006 J. Bone Miner. Metab. pmid:16502128
Mandelin J et al. Human osteoblasts produce cathepsin K. 2006 Bone pmid:16337236
Jono S et al. Vascular calcification in chronic kidney disease. 2006 J. Bone Miner. Metab. pmid:16502129
Van Poznak C et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. 2006 J. Clin. Pathol. pmid:16394281
Mehrotra M et al. Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. 2006 J. Cell. Biochem. pmid:16514640
Yamamoto T et al. Cytokine production in human periodontal ligament cells stimulated with Porphyromonas gingivalis. 2006 J. Periodont. Res. pmid:17076781
Hsu YH et al. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. 2006 Hum. Genet. pmid:16249885
Sandra F et al. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. 2006 Oral Oncol. pmid:16413220
Evans BA et al. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. 2006 J. Bone Miner. Res. pmid:16418778
Berry JE et al. JunB as a downstream mediator of PTHrP actions in cementoblasts. 2006 J. Bone Miner. Res. pmid:16418780
Yang M et al. Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. 2006 Blood pmid:16304045
Galli C et al. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts. 2006 J. Periodontol. pmid:16805686
Holding CA et al. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. 2006 Biomaterials pmid:16806459
Chen G et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. 2006 Cancer pmid:16752412
Gannagé-Yared MH et al. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. 2006 Clin. Endocrinol. (Oxf) pmid:16712667
Rhee EJ et al. The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. 2006 Clin. Endocrinol. (Oxf) pmid:16712673
Tannehill-Gregg SH et al. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. 2006 Clin. Exp. Metastasis pmid:16715352
Yang YQ et al. Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. 2006 Front. Biosci. pmid:16146769
Jia L and Jin TY Combined effect of fluoride and arsenate on gene expression of osteoclast differentiation factor and osteoprotegerin. 2006 Biomed. Environ. Sci. pmid:17190191
Yamaguchi M et al. RANKL increase in compressed periodontal ligament cells from root resorption. 2006 J. Dent. Res. pmid:16861294
Grzegorzewska AE and MÅ‚ot M Serum markers of bone turnover in dialyzed patients separated according to age. 2006 Int Urol Nephrol pmid:16868703
Robertson KM et al. Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. 2006 J. Bone Miner. Res. pmid:16869726

Table of Content